Securing accelerated access to long‐acting injectable cabotegravir for HIV prevention in low‐ and middle‐income countries

INTRODUCTION: Reductions in HIV acquisition have slowed, and the global community is significantly off track from global goals. Oral pre‐exposure prophylaxis (PrEP) alone cannot address the diverse needs of the millions of people at risk of HIV acquisition. Long‐acting injectable cabotegravir (CAB‐L...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenkins, Sarah Y., Resar, Danielle, Panos, Zachary, Staple, Alan, Watkins, Melynda, Ripin, David, Amole, Carolyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338995/
https://www.ncbi.nlm.nih.gov/pubmed/37439082
http://dx.doi.org/10.1002/jia2.26101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338995/
https://www.ncbi.nlm.nih.gov/pubmed/37439082
http://dx.doi.org/10.1002/jia2.26101

Ejemplares similares